Association between thrombotic risk factors and extent of fibrosis in patients with non-alcohol fatty liver diseases

World Journal of Gastroenterology

Volumn 11, Issue 37, 2005, Pages 5834-5839

  Assy, N ^a,b   Bekirov, I ^a   Mejritsky, Y ^a   Solomon, L ^a   Szvalb, S ^a   Hussein, O ^a,b  

^a Rebecca Sieff Government Hospital   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Fibrosis; NAFLD; NASH; Protein C; Protein S; Thrombotic risk factor

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5 LEIDEN; FIBRINOGEN; LUPUS ANTICOAGULANT; PROTEIN C; PROTEIN S; PROTHROMBIN; TECHNETIUM 99M;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; GENE MUTATION; GENETIC RISK; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; LIVER SCINTISCANNING; MALE; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PREVALENCE; RISK FACTOR; THROMBOPHILIA; THROMBOSIS;

EID: 27944502933     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i37.5834     Document Type: Article

References (36)

1. Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001; 96: 2957-2961
2. Bugianesi E, Leone N, Vanni E. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231
4. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000; 45: 1929-1934
5. Bellentani S, Saccoccio G, Masutti F. Prevalence and risk factors for hepatic steatosis in northern Italy. Ann Intern Med 2000; 132: 112-117
6. Marchesini G, Brizi M, Morselli Labate AM. Association of non alcoholic fatty liver disease to insulin resistance. Am J Med 1999; 107: 450-455
7. Mehta K, Van Thiel DH, Shah N, Mobarhan S. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev 2002; 60: 289-293
8. George DK, Goldwurn S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, Powell LW. Increased hepatic iron concentration in non-alcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-318
9. Nolan JP. Intestinal endotoxins as mediators of hepatic injury-an -idea whose time has come again. Hepatology 1989; 10: 887-891
10. Tiegs G. Immunotoxicology of host response mediated experimental liver injury. J Hepatol 1994; 21: 890-903
11. Grove J, Brown AS, Daly AK, Bassendine MF, James OF, Day CP. The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: Effect on age of presentation and dependence on alcohol dehydrogenase genotype. Pharmacogenetics 1998; 8: 335-342
12. Wanless IR, Wong F, Blendis LM. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21: 1238-1247
13. Wanless IR, Lio JJ, Butany J. Role of thrombosis in the pathogenesis of congestive hepatic thrombosis. Hepatology 1995; 21: 1232-1237
14. Wanless IR, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 2004; 24: 99-106
15. Robert A. Two different incubation times for the activated partial thromboplastin time (APTT): a new criterion for diagnosis of lupus anticoagulant. Thromb Haemost 1994; 71: 220-224
16. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-917
17. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703
18. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24: 3-20
19. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474
20. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of CH: diagnosis, grading, and staging. Hepatology 1994; 19: 1513-1520
21. Papatheodoridis GV, Papakonstantinou E, Andrioti E, Cholongitas E, Petraki K, Kontopoulou I, Hadziyannis SJ. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut 2003; 52: 404-409
22. Cucuianu M, Brudasca I, Trif I, Stancu. A. Clinical studies on plasma protein C. Correlation with serum cholinesterase. Nouv Rev Fr Hematol 1993; 35: 481-486
23. Bruckert E, Ankri A, Jung M, Turpin G, De Gennes JL. Mild liver abnormalities associated with elevated plasma factor VII and protein C in hypertriglyceridaemic patients. Eur J Med 1993; 2: 461-465
24. Friedman SL. Liver fibrosis -from bench to bedside. J Hepatol 2003; 38: S38-53
25. Brenner DA, Waterboer T, Choi SK, Lindquist JN, Stefanovic B, Burchardt E, Yamauchi M, Gillan A, Rippe RA. New aspects of hepatic fibrosis. J Hepatol 2000; 32: 32-38
26. Wanless IR, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 2004; 24: 99-106
27. Assy N, Hussein O, Khalil A, Luder A, Szvalb S, Paizi M, Spira G. The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. Dig Dis Sci 2005 -in press
28. Papatheodoridis GV, Burroughs AK. Hemostasis in hepatic and biliary disorders. In: LH Blumgart, Fong Y, eds. Surgery of the liver and biliary tract. London WB Saunders 2000: 199-213
29. Green AF, Rantoff OD. Elevated antihaemophilic factor (AHF, factor VIII) procoagulant activity and AHF-like antigen in alcoholic cirrhosis of the liver. J Lab Clin Med 1974; 83: 189-197
30. Marra F, DeFranco R, Grappone C. Expression of the thrombin receptor in human liver: up-regulation during acute and chronic injury. Hepatology 1998; 27: 462-471
31. Marra F, Grandaliano G, Valente AJ. Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: potential role in liver injury. Hepatology 1995; 22: 780-787
32. Duplantier JG, Dubuisson L, Senant N, Freyburger G, Laurendeau I, Herbert JM, Desmouliere A, Rosenbaum J. A role for thrombin in liver fibrosis. Gut 2004; 53: 1682-1687
33. Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002; 31: 256-263
34. Ordi-Ros J, Villarreal J, Monegal F. Anticardiolipin antibodies in patients with chronic hepatitis C virus infection: characterization in relation to antiphospholipid syndrome. Clin Diagn Lab Immunol 2000; 7: 241-244
35. Beauchamp NJ, Dykes AC, Parikh N, Campbell Tait R, Daly ME. The prevalence of, and molecular defects underlying, inherited protein S deficiency in the general population. Br J Haematol 2004; 125: 647-654
36. Yoshikawa A, Kaido T, Seto SI, Katsuura Y, Imamura M. Activated protein C prevents multiple organ injury following extensive hepatectomy in cirrhotic rats. J Hepatol 2000; 33: 953-960